comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists An Observational Study of of vs Glucagon-Like Peptide-1 Receptor Results of cardiovascular outcomes trials
Description
Annu Rev Med
Sharif S, Van der Graaf Y, Cramer MJ, Kapelle LJ, de Borst GJ, Visseren FLJ, Westerink J, group Ss
Since then, recommendations have been developed for such an up-titration (dose escalation) approach to induce tolerance before patients are exposed to higher doses of GLP-1 RAs (Figure 2)
Instead, compounded alternatives may be prescribed when clinically appropriate and legally permissible
Int J Mol Sci (2022) 23(2):739
"People think constipation is just constipation, but that constipation can turn into intestinal obstruction that can cause perforation and people can die," says Kessler
00032-X/asset/f312f4e3-50d1-472f-90c9-896e4cef8e23/main.assets/gr1_lrg.jpg)
